Skip to main content
SpringerLink
Log in
Book cover

Clinical Trials in Neurology pp 505–513Cite as

Myopathies: Ethics, Outcome Variables and Clinical Scales

  • Chapter

  • 262 Accesses

Abstract

Large-scale trials of therapy in muscle disease have been relatively rare. This may be related to the rarity of many individual muscle diseases, the lack of understanding of the pathogenesis of these diseases, and the limited number of rational therapies available. The chronic nature of some of the muscle diseases makes short-duration clinical trials of limited value.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kakulas BA. Problems and potential for gene therapy in Duchenne muscular dystrophy. Neuromusc Disord 1997; 7: 319–324.

    Article  PubMed  CAS  Google Scholar 

  2. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974; II: 1409–1412.

    Article  Google Scholar 

  3. Munsat TL, Walton JN. Prednisone in Duchenne muscular dystrophy. Lancet 1975; I: 276–277.

    Article  Google Scholar 

  4. Dubowitz V. 47th ENMC International Workshop: treatment of muscular dystrophy. Neuromusc Disord 1997;7:261–267.

    Google Scholar 

  5. Dubrovsky AL, Angelini C, Bonifati DM, Pegoraro E, Mesa L. Steroids in muscular dystrophy: where do we stand? Neuro-musc Disord 1998; 8: 380–384.

    Article  CAS  Google Scholar 

  6. Fenichel GM, Mendell JR, Moxley III RT, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991; 48: 575–579.

    Article  PubMed  CAS  Google Scholar 

  7. Mendell JR, Province MA, Moxley III RT, et al. Clinical investigation of Duchenne muscular dystrophy: a methodology for therapeutic trials based on natural history controls. Arch Neurol 1987; 44: 808–811.

    Article  PubMed  CAS  Google Scholar 

  8. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. N Engl J Med 1989; 320: 1592–1597.

    Article  PubMed  CAS  Google Scholar 

  9. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991; 41: 1874–1877.

    Article  PubMed  CAS  Google Scholar 

  10. Griggs RC, Moxley III RT, Mendell JR, et al. Prednisone in Duchenne dystrophy. Arch Neurol 1991; 48: 383–388.

    Article  PubMed  CAS  Google Scholar 

  11. Griggs RC, Moxley III RT, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43: 520–527.

    Article  PubMed  CAS  Google Scholar 

  12. Fenichel G, Pestronk A, Florene J, Robison V, Hemelt V. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997; 48: 1225–1226.

    Article  PubMed  CAS  Google Scholar 

  13. DeSilva S, Drachman DB, Mellitis D, Kund RW. Prednisone treatment in Duchenne muscular dystrophy: long term benefit. Arch Neurol 1987; 44: 818–822.

    Article  PubMed  CAS  Google Scholar 

  14. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993; 43: 527–532.

    Article  PubMed  CAS  Google Scholar 

  15. Granata C, Merlini L, Cervellati S, et al. Long-term results of spine surgery in Duchenne muscular dystrophy. Neuromusc Disord 1996; 6: 61–68.

    Article  PubMed  CAS  Google Scholar 

  16. Scheuerbrandt G. DMD meeting. Treatment of Duchenne muscular dystrophy. Neuromusc Disord 1998; 8: 213–219.

    Article  PubMed  CAS  Google Scholar 

  17. Vignos PJ, Wagner MB, Karlinchak B, Katirji B Evaluation of a program for long-term treatment of Duchenne muscular dystrophy. J Bone Joint Surg AM 1996; 78: 1844–1852.

    PubMed  CAS  Google Scholar 

  18. Karpati G, Gilbert R, Petrof BJ, Nalbantoglu J. Gene therapy research for Duchenne and Becker muscular dystrophies. Curr Opin Neuro 1997; 10: 430–435.

    Article  CAS  Google Scholar 

  19. Karpati G, Lochmuller H. The scope of gene therapy in humans: scientific, safety and ethical considerations. Neuro-musc Disord 1997; 7: 273–276.

    Article  CAS  Google Scholar 

  20. Dennis CL, Tinsley JM, Deconinck AE, Davies KE. Molecular and functional analysis of the utrophin promoter source. Nucleic Acids Res 1996; 24: 1646–1652.

    Article  PubMed  CAS  Google Scholar 

  21. Karpati G, Ajdukovic D, Arnold D, et al. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 1993; 34: 8–17.

    Article  PubMed  CAS  Google Scholar 

  22. Gussoni E, Paviath GK, Lanctot AM, et al. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 1992; 356: 435–438.

    Article  PubMed  CAS  Google Scholar 

  23. Tawil R, Figlewicz DA, Griggs RC, Weiffenbach B. Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium. Ann Neurol 1998; 43: 279–282.

    Article  PubMed  CAS  Google Scholar 

  24. Tawil R, McDermott MP, Panya S, et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. Neurology 1997; 48: 46–49.

    Article  PubMed  CAS  Google Scholar 

  25. Tawil R, Herr BE, Moxley RT, et al. Dual-energy x-ray absorptiometry: quantifying muscle mass in therapeutic trials [abstract]. Ann Neurol 1994; 36: 320.

    Article  Google Scholar 

  26. FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997; 48: 38–46.

    Article  Google Scholar 

  27. Kissel JT, McDermott MP, Natarajan R, et al. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology 1998; 50: 1402–1406.

    Article  PubMed  CAS  Google Scholar 

  28. Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a 02-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci 1992; 83: 615–621.

    PubMed  CAS  Google Scholar 

  29. Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a [3adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci 1993; 84: 651–654.

    PubMed  CAS  Google Scholar 

  30. Personius KE, Pandya S, King W, Tawil R, McDermott MP, FSH DY Group. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther 1994; 74: 253–263.

    PubMed  Google Scholar 

  31. Hirano M, DiMauro S. Clinical features of mitochondrial myopathies and encephalomyopathies. In: Lane RJM, editor. Handbook of muscle disease. New York: Marcel Dekker, 1996: 479–504.

    Google Scholar 

  32. Cooper JM, Schapira AHV. Clinical features of mitochondrial myopathies and encephalomyopathies. In: Lane RJM, editor. Handbook of muscle disease. New York: Marcel Dekker, 1996: 519–531.

    Google Scholar 

  33. Taylor RW, Chinnery PE, Turnbull DM, Lightowler RN. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nature Genet 1997; 15: 212–215.

    Article  PubMed  CAS  Google Scholar 

  34. Taivassalo T, Matthews PM, De Stefano N, et al. Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency. Neurology 1996: 47: 529–534.

    Article  PubMed  CAS  Google Scholar 

  35. Eleff S, Kennaway NG, Buist NRM, et al. 31P NMP study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci USA 1984; 81: 3529–3533.

    Article  PubMed  CAS  Google Scholar 

  36. Matthews PM, Ford B, Danduran RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial diseases. Neurology 1993; 43: 884–890.

    Article  PubMed  CAS  Google Scholar 

  37. Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNAL°(°°R) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992; 42: 2147–2152.

    Article  PubMed  CAS  Google Scholar 

  38. Lane RJM, Shelbourne P, Johnson KJ. Myotonic dystrophy. In: Lane RJM, editor. Handbook of muscle disease. New York: Marcel Dekker, 1996: 311–328.

    Google Scholar 

  39. Finlay M. A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1982; 45: 461–463.

    Article  PubMed  CAS  Google Scholar 

  40. Grant R, Sutton DL, Behan PO, Ballantyne JP. Nifedipine in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1987; 50: 199–206.

    Article  PubMed  CAS  Google Scholar 

  41. Griggs RC, Pandya S, Florence JM, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989; 39: 219–222.

    Article  PubMed  CAS  Google Scholar 

  42. Orndahl G, Grimby G, Grimby A, Johansson G, Wilhelmsen L. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy: a placebo-controlled study. J Intern Med 1994; 235: 205–210.

    CAS  Google Scholar 

  43. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy: a clinical research center study. J Clin Endocrinol Metab 1995; 80: 3715–3723.

    Article  PubMed  CAS  Google Scholar 

  44. Lane RJM, Hudgson P. Idiopathic inflammatory myopathies. In: Lane RJM, editor. Handbook of muscle disease. New York: Marcel Dekker, 1996: 539–573.

    Google Scholar 

  45. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980; 92: 365–369.

    PubMed  CAS  Google Scholar 

  46. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. New England Journal of Medicine 1993; 329: 1993–2000.

    Article  PubMed  CAS  Google Scholar 

  47. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43: 876–879.

    Article  PubMed  CAS  Google Scholar 

  48. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993; 72: 225–235.

    Article  PubMed  CAS  Google Scholar 

  49. Convery FR, Minteer MA, Amiel D, Connett KL. Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 1997; 58: 494–499.

    Google Scholar 

Download references

Authors
  1. R. W. Orrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. J. Guiloff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neuromuscular Unit, West London Neurosciences Centre, 1st Floor Pilot Wing, Charing Cross Hospital, Fulham Palace Road, W6 8RF, London, UK

    Roberto J. Guiloff MD, FRCP (Consultant Neurologist) (Consultant Neurologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag London

About this chapter

Cite this chapter

Orrell, R.W., Guiloff, R.J. (2001). Myopathies: Ethics, Outcome Variables and Clinical Scales. In: Guiloff, R.J. (eds) Clinical Trials in Neurology. Springer, London. https://doi.org/10.1007/978-1-4471-3787-0_40

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3787-0_40

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-856-0

  • Online ISBN: 978-1-4471-3787-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation